Format

Send to

Choose Destination
Hum Reprod. 2003 Aug;18(8):1737-46.

Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis.

Author information

1
Free University of Berlin, Clinical Research Center of Women's Health, Klingsorst 109a, D-12203 Berlin, Germany. martina.doeren@medizin.fu-berlin.de

Abstract

BACKGROUND:

Long-term post-menopausal hormone therapy (pHT) was often regarded as first-line therapy to prevent fractures in post-menopausal women, a recommendation under scrutiny given the benefit-risk profile of the Women's Health Initiative results of the estrogen-progestin combination. Apart from controlled clinical studies providing data with fractures as an end point, measures of lumbar and hip bone mineral density (BMD) may be used to assess bone-related effects of pHT. The objective of this study was to conduct a systematic review of 2-year trials, published between 1990 and December 2002, and assessing changes in BMD by any estrogen including ethinyl estradiol, any estrogen plus any progestin, or tibolone.

METHODS:

We searched MEDLINE, EMBASE and systematic reviews. Thirty-nine randomized, prospective, controlled 2-year trials were analysed in pre-specified groups according to the profile of the compounds.

RESULTS:

Virtually all pHT regimens at least maintain BMD at the lumbar spine and the hip compared with baseline; there is no apparent difference between the various estrogenic compounds. Tibolone, a synthetic progestin, appears to be as effective as any estrogen. Most trials were conducted in early post-menopausal women, fewer in women with hysterectomy and/or bilateral oophorectomy.

CONCLUSIONS:

The size of impact on BMD does not appear to differ between tibolone and any estrogen compound studied.

PMID:
12871893
DOI:
10.1093/humrep/deg315
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center